Clinical trial · no report yet · Phase 1/Phase 2
Morpheus-panBC
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- NCT03424005 ↗
- Recruiting
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Capecitabine; Atezolizumab; Ipatasertib; SGN-LIV1A; Bevacizumab; Chemotherapy (Gemcitabine + Carboplatin or Eribulin); Selicrelumab; Tocilizumab; Nab-Paclitaxel; Sacituzumab Govitecan; Abemaciclib; Fulvestrant; Ribociclib (Dose #1); Inavolisib (Dose #1); Trastuzumab Deruxtecan; Ribociclib (Dose #2); Letrozole; Inavolisib (Dose #2); Empagliflozin; Palbociclib; Metformin; Atirmociclib; Giredestrant
- Arms
- Atezolizumab + Nab-Paclitaxel · Active comparator
- Atezolizumab + Nab-Paclitaxel + Tocilizumab · Experimental
- Atezolizumab + Sacituzumab Govitecan · Experimental
- Capecitabine · Active comparator
- Atezolizumab + Ipatasertib · Experimental
- Atezolizumab + SGN-LIV1A · Experimental
- Atezolizumab + Selicrelumab + Bevacizumab · Experimental
- Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin) · Experimental
- Inavolisib (Dose #2) + Abemaciclib + Fulvestrant · Experimental
- Inavolisib (Dose #2) + Ribociclib (Dose #1) + Fulvestrant · Experimental
- Inavolisib (Dose #2) + Ribociclib (Dose #1) + Letrozole · Experimental
- Inavolisib (Dose #2) + Ribociclib (Dose #2) + Fulvestrant · Experimental
- Inavolisib (Dose #2) + Ribociclib (Dose #2) + Letrozole · Experimental
- Inavolisib (Dose #2) + Abemaciclib + Letrozole · Experimental
- Inavolisib (Dose #1) + Trastuzumab Deruxtecan · Experimental
- Inavolisib (Dose #2) + Trastuzumab Deruxtecan · Experimental
- Empagliflozin + Inavolisib (Dose #2) + Fulvestrant ± Palbociclib · Experimental
- Metformin + Inavolisib (Dose #2) + Fulvestrant ± Palbociclib · Experimental
- Inavolisib (Dose #2) + Atirmociclib (Atirmo) + Fulvestrant · Experimental
- Inavolisib (Dose #1) + Abemaciclib + Letrozole · Experimental
- Inavolisib (Dose #1) + Abemaciclib + Giredestrant · Experimental
- Inavolisib (Dose #2) + Abemaciclib + Giredestrant · Experimental
- Inavolisib (Dose #2) + Ribociclib (Dose #1) + Giredestrant · Experimental
- Enrollment
- 1,132 (estimated)
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- Hoffmann-La Roche with Gilead Sciences, Pfizer
- Start
- Mar 30, 2018
- Primary completion
- Sep 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT03424005 · updated Oct 9, 2026